Skip to main content

Reimbursement

Value based concerns for Oncologist in the United States


The definition of value by patients with cancer does not necessarily coincide with other definitions by other stakeholders. According to one breast cancer advocate, when patients are asked to define “value” in the context of their cancer treatment, cost is not the first thing that comes to mind. Read More ›

Payment models that align reimbursement to support treatment planning and care coordination encourage oncology care providers to adhere to cancer treatment pathways, said Jennifer Malin, MD, PhD, Staff Vice President for Clinical Strategy, Anthem, Thousand Oaks, CA, at the 2015 American Society of Clinical Oncology annual meeting. Read More ›


According to a recent study, 63.6% of oncologists surveyed favor the establishment of an independent panel of health experts to decide which treatments Medicare will pay for based on a cost-benefit analysis (Gogineni K, et al. J Clin Oncol. 2015;33:846-853). Less than 50% of patients and members of the general public think this is a good idea. The United Kingdom’s National Institute for Health and Care Excellence (NICE) is one model for such a panel. Read More ›




The Value of the Patient’s Voice in Policy Formation
According to Dr. Bosserman, it is the oncology provider’s responsibility to make the patient’s voice heard among policymakers. This is how they ensure that patients achieve the best health outcomes. Read More ›

Page 6 of 9